BioAffinity Technologies, Net Worth
BioAffinity Technologies, Net Worth Breakdown | BIAF |
BioAffinity Technologies, Net Worth Analysis
BioAffinity Technologies,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BioAffinity Technologies,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BioAffinity Technologies,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BioAffinity Technologies,'s net worth analysis. One common approach is to calculate BioAffinity Technologies,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BioAffinity Technologies,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BioAffinity Technologies,'s net worth. This approach calculates the present value of BioAffinity Technologies,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BioAffinity Technologies,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BioAffinity Technologies,'s net worth. This involves comparing BioAffinity Technologies,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BioAffinity Technologies,'s net worth relative to its peers.
Enterprise Value |
|
To determine if BioAffinity Technologies, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioAffinity Technologies,'s net worth research are outlined below:
| BioAffinity Technologies, generated a negative expected return over the last 90 days | |
| BioAffinity Technologies, has high historical volatility and very poor performance | |
| BioAffinity Technologies, has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies, has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies, currently holds 1.58 M in liabilities. bioAffinity Technologies, has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies,'s use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies, currently holds about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: bioAffinity stock hits 52-week low at 0.26 amid market challenges - Investing.com |
BioAffinity Technologies, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in bioAffinity Technologies,. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioAffinity Technologies,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know BioAffinity Technologies,'s Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioAffinity Technologies, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading bioAffinity Technologies, backward and forwards among themselves. BioAffinity Technologies,'s institutional investor refers to the entity that pools money to purchase BioAffinity Technologies,'s securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-12-31 | 6.3 K | Oarsman Capital, Inc | 2024-12-31 | 2.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 500 | Clear Street Llc. | 2024-09-30 | 100.0 | Bank Of America Corp | 2024-12-31 | 84.0 | Jpmorgan Chase & Co | 2024-12-31 | 21.0 | Ground Swell Capital, Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-12-31 | 260.9 K | Geode Capital Management, Llc | 2024-12-31 | 99.6 K |
Follow BioAffinity Technologies,'s market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.81 M.Market Cap |
|
Project BioAffinity Technologies,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.19) | (1.25) | |
| Return On Capital Employed | (1.53) | (1.46) | |
| Return On Assets | (0.87) | (0.91) | |
| Return On Equity | (1.88) | (1.79) |
When accessing BioAffinity Technologies,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures BioAffinity Technologies,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioAffinity Technologies,'s profitability and make more informed investment decisions.
Evaluate BioAffinity Technologies,'s management efficiency
bioAffinity Technologies, has return on total asset (ROA) of (0.6978) % which means that it has lost $0.6978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5152) %, meaning that it created substantial loss on money invested by shareholders. BioAffinity Technologies,'s management efficiency ratios could be used to measure how well BioAffinity Technologies, manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.25. The BioAffinity Technologies,'s current Return On Capital Employed is estimated to increase to -1.46. At this time, BioAffinity Technologies,'s Fixed Asset Turnover is most likely to increase slightly in the upcoming years. The BioAffinity Technologies,'s current Asset Turnover is estimated to increase to 0.29, while Non Currrent Assets Other are projected to decrease to roughly 10 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.50 | 0.52 | |
| Tangible Book Value Per Share | 0.27 | 0.28 | |
| Enterprise Value Over EBITDA | (1.37) | (1.44) | |
| Price Book Value Ratio | 2.38 | 2.50 | |
| Enterprise Value Multiple | (1.37) | (1.44) | |
| Price Fair Value | 2.38 | 2.50 | |
| Enterprise Value | 13.4 M | 12.7 M |
Evaluating the management effectiveness of BioAffinity Technologies, allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The BioAffinity Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 0.6346 | Revenue | Quarterly Revenue Growth 120.474 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAffinity Technologies, insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAffinity Technologies,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioAffinity Technologies, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioAffinity Technologies, time-series forecasting models is one of many BioAffinity Technologies,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioAffinity Technologies,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
BioAffinity Technologies, Earnings per Share Projection vs Actual
BioAffinity Technologies, Corporate Management
| Timothy JD | Secretary VP | Profile | |
| Dallas Coleman | National Sales | Profile | |
| William Bauta | Senior Therapeutics | Profile | |
| Maria JD | President, Founder | Profile | |
| Xavier MS | VP Operations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 120.474 | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.